Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...

A new research paper was published in Oncotarget's Volume 16 on January 21, 2025, titled "Assessment of cfDNA release dynamics during colorectal cancer surgery." Researchers from the University of ...

Hamilton, a global leader in precision liquid handling and laboratory automation, and nRichDX, a leader in liquid biopsy ...

“Taken together, our results suggest that in addition to physiological age, comorbidities and unfavorable clinical traits, intense surgical manipulation from the tumor's extent, may result in greater ...

Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct . The study, which was conducted by ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

The study authors said the method also has the advantages of having a quick turnaround and a relatively low cost. The study authors noted that ALL is the most common pediatric malignancy, but in a ...

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer Among 25 patients, pretreatment plasma samples were sequenced ...

Next-generation sequencing (NGS) is an important component of first-line treatment selection for metastatic non–small-cell lung cancer (NSCLC) and is typically ordered by medical oncologists in the ...